---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046254"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:45:14.731875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma reports Q3 net loss $44.6M; cash $460.7M funds into 2027

## Summary
- Net loss of $44.6M for Q3 2024, improved from $50.9M in Q3 2023; non-GAAP net loss $37.1M.
- Cash, cash equivalents and marketable securities $460.7M as of Sept 30, 2024; provides runway into 2027.
- Completed ImmPACT Bio acquisition; added IMPT-314, a CD19/CD20 CAR T candidate with Phase 1 data at ASH 2024.
- Expect to initiate pivotal trial for IMPT-314 in 2025 in relapsed/refractory LBCL; initial Phase 1 data at ASH Dec 9.
- Phase 1 trial of LYL119 for ROR1-positive solid tumors ongoing; initial clinical data expected H2 2025.

## SEC filing metadata
- accession: 0001628280-24-046254
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828024046254/0001628280-24-046254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828024046254/lyel-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046254
- JSON: https://secwatch.observer/filing/0001628280-24-046254.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.